Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives.

Scientia pharmaceutica

Nosulenko IS, Voskoboynik OY, Berest GG, Safronyuk SL, Kovalenko SI, Kamyshnyi OM, Polishchuk NM, Sinyak RS, Katsev AV.
PMID: 25853063
Sci Pharm. 2014 Mar 24;82(3):483-500. doi: 10.3797/scipharm.1402-10. Print 2014.

Potassium 8-R(1)-9-R(2)-10-R(3)-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-thiolates 2.1-2.26 were synthesized via cyclocondensation of 6-R-3-(3-R(1)-4-R(2)-5-R(3)-aminophenyl)-1,2,4-triazin-5-ones 1.1-1.26 with carbon disulfide, potassium hydroxide, and ethanol or with potassium O-ethyl dithiocarbonate in 2-propanol. The corresponding thiones 3.1-3.26 were obtained by treatment of 2.1-2.26 with hydrochloric acid. It was...

Cite
Nosulenko IS, Voskoboynik OY, Berest GG, et al. Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives. Sci Pharm. 2014;82(3):483-500doi: 10.3797/scipharm.1402-10.
Nosulenko, I. S., Voskoboynik, O. Y., Berest, G. G., Safronyuk, S. L., Kovalenko, S. I., Kamyshnyi, O. M., Polishchuk, N. M., Sinyak, R. S., & Katsev, A. V. (2014). Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives. Scientia pharmaceutica, 82(3), 483-500. https://doi.org/10.3797/scipharm.1402-10
Nosulenko, Inna S, et al. "Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives." Scientia pharmaceutica vol. 82,3 (2014): 483-500. doi: https://doi.org/10.3797/scipharm.1402-10
Nosulenko IS, Voskoboynik OY, Berest GG, Safronyuk SL, Kovalenko SI, Kamyshnyi OM, Polishchuk NM, Sinyak RS, Katsev AV. Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives. Sci Pharm. 2014 Mar 24;82(3):483-500. doi: 10.3797/scipharm.1402-10. Print 2014. PMID: 25853063; PMCID: PMC4318151.
Copy Download .nbib Format: NLM
Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides.

The Journal of organic chemistry

Lebedev AY, Khartulyari AS, Voskoboynikov AZ.
PMID: 15651807
J Org Chem. 2005 Jan 21;70(2):596-602. doi: 10.1021/jo048671t.

Palladium-catalyzed cyclization of arylhydrazones of 2-bromoaldehydes and 2-bromoacetophenones to give 1-aryl-1H-indazoles has been studied in detail. The cyclization of arylhydrazone of 2-bromobenzaldehydes can be performed with good to high yields using Pd(dba)2 and chelating phosphines, of which the most...

Cite
Lebedev AY, Khartulyari AS, Voskoboynikov AZ. Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides. J Org Chem. 2005;70(2):596-602doi: 10.1021/jo048671t.
Lebedev, A. Y., Khartulyari, A. S., & Voskoboynikov, A. Z. (2005). Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides. The Journal of organic chemistry, 70(2), 596-602. https://doi.org/10.1021/jo048671t
Lebedev, Artyom Y, et al. "Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides." The Journal of organic chemistry vol. 70,2 (2005): 596-602. doi: https://doi.org/10.1021/jo048671t
Lebedev AY, Khartulyari AS, Voskoboynikov AZ. Synthesis of 1-aryl-1H-indazoles via palladium-catalyzed intramolecular amination of aryl halides. J Org Chem. 2005 Jan 21;70(2):596-602. doi: 10.1021/jo048671t. PMID: 15651807.
Copy Download .nbib Format: NLM
Substituted 2-[(2-Oxo-2H-[1,2,4]triazino [2,3-c]quinazolin-6-yl)thio]acetamides with Thiazole and Thiadiazole Fragments: Synthesis, Physicochemical Properties, Cytotoxicity, and Anticancer Activity.

Scientia pharmaceutica

Kovalenko SI, Nosulenko IS, Voskoboynik AY, Berest GG, Antypenko LN, Antypenko AN, Katsev AM.
PMID: 23264935
Sci Pharm. 2012 Oct-Dec;80(4):837-65. doi: 10.3797/scipharm.1208-07. Epub 2012 Oct 04.

The series of novel N-R-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)thio]acetamides with thiazole and thiadiazole fragments in a molecule were obtained by alkylation of potassium salts 1.1-1.4 by N-hetaryl-2-chloroacetamides and by aminolysis of activated acids 2.1-2.4 with N,N'-carbonyldiimidazole (CDI). The structures of compounds were determined...

Cite
Kovalenko SI, Nosulenko IS, Voskoboynik AY, et al. Substituted 2-[(2-Oxo-2H-[1,2,4]triazino [2,3-c]quinazolin-6-yl)thio]acetamides with Thiazole and Thiadiazole Fragments: Synthesis, Physicochemical Properties, Cytotoxicity, and Anticancer Activity. Sci Pharm. 2012;80(4):837-65doi: 10.3797/scipharm.1208-07.
Kovalenko, S. I., Nosulenko, I. S., Voskoboynik, A. Y., Berest, G. G., Antypenko, L. N., Antypenko, A. N., & Katsev, A. M. (2012). Substituted 2-[(2-Oxo-2H-[1,2,4]triazino [2,3-c]quinazolin-6-yl)thio]acetamides with Thiazole and Thiadiazole Fragments: Synthesis, Physicochemical Properties, Cytotoxicity, and Anticancer Activity. Scientia pharmaceutica, 80(4), 837-65. https://doi.org/10.3797/scipharm.1208-07
Kovalenko, Sergey I, et al. "Substituted 2-[(2-Oxo-2H-[1,2,4]triazino [2,3-c]quinazolin-6-yl)thio]acetamides with Thiazole and Thiadiazole Fragments: Synthesis, Physicochemical Properties, Cytotoxicity, and Anticancer Activity." Scientia pharmaceutica vol. 80,4 (2012): 837-65. doi: https://doi.org/10.3797/scipharm.1208-07
Kovalenko SI, Nosulenko IS, Voskoboynik AY, Berest GG, Antypenko LN, Antypenko AN, Katsev AM. Substituted 2-[(2-Oxo-2H-[1,2,4]triazino [2,3-c]quinazolin-6-yl)thio]acetamides with Thiazole and Thiadiazole Fragments: Synthesis, Physicochemical Properties, Cytotoxicity, and Anticancer Activity. Sci Pharm. 2012 Oct-Dec;80(4):837-65. doi: 10.3797/scipharm.1208-07. Epub 2012 Oct 04. PMID: 23264935; PMCID: PMC3528059.
Copy Download .nbib Format: NLM
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Journal for immunotherapy of cancer

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.
PMID: 30760319
J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

Cite
Berry S, Giraldo N, Nguyen P, et al. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer. 2019;7(1):46doi: 10.1186/s40425-019-0519-y.
Berry, S., Giraldo, N., Nguyen, P., Green, B., Xu, H., Ogurtsova, A., Soni, A., Succaria, F., Wang, D., Roberts, C., Stein, J., Engle, E., Pardoll, D., Anders, R., Cottrell, T., Taube, J. M., Tran, B., Voskoboynik, M., Kuo, J., Bang, Y. L., Chung, H. C., Ahn, M. J., Kim, S. W., Perera, A., Freeman, D., Achour, I., Faggioni, R., Xiao, F., Ferte, C., Lemech, C., Meric-Bernstam, F., Werner, T., Hodi, S., Messersmith, W., Lewis, N., Talluto, C., Dostalek, M., Tao, A., McWhirter, S., Trujillo, D., Luke, J., Xu, C., BoMarelli, Qi, J., Qin, G., Yu, H., Jenkins, M., Lo, K. M., Halle, J. P., Lan, Y., Taylor, M., Vogelzang, N., Cohn, A., Stepan, D., Shumaker, R., Dutcus, C., Guo, M., Schmidt, E., Rasco, D., Brose, M., Vogelzang, N., Di Simone, C., Jain, S., Richards, D., Encarnacion, C., Rasco, D., Shumaker, R., Dutcus, C., Stepan, D., Guo, M., Schmidt, E., Taylor, M., Vogelzang, N., Encarnacion, C., Cohn, A., Di Simone, C., Rasco, D., Richards, D., Taylor, M., Dutcus, C., Stepan, D., Shumaker, R., Guo, M., Schmidt, E., Mier, J., An, J., Yang, Y. Y., Lee, W. H., Yang, J., Kim, J. K., Kim, H. G., Paek, S. H., Lee, J. W., Woo, J., Kim, J. B., Kwon, H., Lim, W., Paik, N. S., Kim, Y. K., Moon, B. I., Janku, F., Tan, D., Martin-Liberal, J., Takahashi, S., Geva, R., Gucalp, A., Chen, X., Subramanian, K., Mataraza, J., Wheler, J., & Bedard, P. (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). Journal for immunotherapy of cancer, 7(1), 46. https://doi.org/10.1186/s40425-019-0519-y
Berry, Sneha, et al. "Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)." Journal for immunotherapy of cancer vol. 7,1 (2019): 46. doi: https://doi.org/10.1186/s40425-019-0519-y
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y. PMID: 30760319; PMCID: PMC6373015.
Copy Download .nbib Format: NLM
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.

Clinical lung cancer

Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S.
PMID: 32778511
Clin Lung Cancer. 2021 May;22(3):e425-e430. doi: 10.1016/j.cllc.2020.06.001. Epub 2020 Jun 10.

BACKGROUND: The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non-small-cell lung cancer (NSCLC) is unclear.MATERIALS AND METHODS: We identified patients with metastatic NSCLC treated with the anti-programmed death...

Cite
Samuel E, Lie G, Balasubramanian A, et al. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clin Lung Cancer. 2020;22(3):e425-e430doi: 10.1016/j.cllc.2020.06.001.
Samuel, E., Lie, G., Balasubramanian, A., Hiong, A., So, Y., Voskoboynik, M., Moore, M., Shackleton, M., Haydon, A., John, T., Mitchell, P. L. R., Markman, B., Briggs, P., & Parakh, S. (2021). Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical lung cancer, 22(3), e425-e430. https://doi.org/10.1016/j.cllc.2020.06.001
Samuel, Evangeline, et al. "Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC." Clinical lung cancer vol. 22,3 (2021): e425-e430. doi: https://doi.org/10.1016/j.cllc.2020.06.001
Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clin Lung Cancer. 2021 May;22(3):e425-e430. doi: 10.1016/j.cllc.2020.06.001. Epub 2020 Jun 10. PMID: 32778511.
Copy Download .nbib Format: NLM
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.

British journal of cancer

Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M.
PMID: 34795408
Br J Cancer. 2021 Nov 18; doi: 10.1038/s41416-021-01632-2. Epub 2021 Nov 18.

BACKGROUND: Pamiparib, a PARP1/2 inhibitor, demonstrated antitumor activity in preclinical models.METHODS: This Phase 1A/1B dose-escalation/dose-expansion study enrolled adults (≥18 years) with advanced/metastatic cancer. The dose-escalation phase evaluated the recommended Phase 2 dose (RP2D), maximum tolerated dose (MTD), and pharmacokinetics;...

Cite
Lickliter JD, Voskoboynik M, Mileshkin L, et al. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer. 2021;doi: 10.1038/s41416-021-01632-2.
Lickliter, J. D., Voskoboynik, M., Mileshkin, L., Gan, H. K., Kichenadasse, G., Zhang, K., Zhang, M., Tang, Z., & Millward, M. (2021). Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. British journal of cancer, . https://doi.org/10.1038/s41416-021-01632-2
Lickliter, Jason D, et al. "Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours." British journal of cancer vol. (2021). doi: https://doi.org/10.1038/s41416-021-01632-2
Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer. 2021 Nov 18; doi: 10.1038/s41416-021-01632-2. Epub 2021 Nov 18. PMID: 34795408.
Copy Download .nbib Format: NLM
Hafnium vs. Zirconium, the Perpetual Battle for Supremacy in Catalytic Olefin Polymerization: A Simple Matter of Electrophilicity?.

Polymers

Vittoria A, Goryunov GP, Izmer VV, Kononovich DS, Samsonov OV, Zaccaria F, Urciuoli G, Budzelaar PHM, Busico V, Voskoboynikov AZ, Uborsky DV, Ehm C, Cipullo R.
PMID: 34451163
Polymers (Basel). 2021 Aug 06;13(16). doi: 10.3390/polym13162621.

The performance of

Cite
Vittoria A, Goryunov GP, Izmer VV, et al. Hafnium vs. Zirconium, the Perpetual Battle for Supremacy in Catalytic Olefin Polymerization: A Simple Matter of Electrophilicity?. Polymers (Basel). 2021;13(16)doi: 10.3390/polym13162621.
Vittoria, A., Goryunov, G. P., Izmer, V. V., Kononovich, D. S., Samsonov, O. V., Zaccaria, F., Urciuoli, G., Budzelaar, P. H. M., Busico, V., Voskoboynikov, A. Z., Uborsky, D. V., Ehm, C., & Cipullo, R. (2021). Hafnium vs. Zirconium, the Perpetual Battle for Supremacy in Catalytic Olefin Polymerization: A Simple Matter of Electrophilicity?. Polymers, 13(16), . https://doi.org/10.3390/polym13162621
Vittoria, Antonio, et al. "Hafnium vs. Zirconium, the Perpetual Battle for Supremacy in Catalytic Olefin Polymerization: A Simple Matter of Electrophilicity?." Polymers vol. 13,16 (2021). doi: https://doi.org/10.3390/polym13162621
Vittoria A, Goryunov GP, Izmer VV, Kononovich DS, Samsonov OV, Zaccaria F, Urciuoli G, Budzelaar PHM, Busico V, Voskoboynikov AZ, Uborsky DV, Ehm C, Cipullo R. Hafnium vs. Zirconium, the Perpetual Battle for Supremacy in Catalytic Olefin Polymerization: A Simple Matter of Electrophilicity?. Polymers (Basel). 2021 Aug 06;13(16). doi: 10.3390/polym13162621. PMID: 34451163; PMCID: PMC8400551.
Copy Download .nbib Format: NLM
A Simple and Convenient Method for the Synthesis of 1-Methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones and Their Substituted Derivatives.

Acta chimica Slovenica

Kazunin MS, Voskoboynik OY, Shishkina SV, Antypenko OM, Kovalenko SI.
PMID: 33855556
Acta Chim Slov. 2020 Jun;67(2):586-593.

A simple and effective method for the synthesis of unknown 1-methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones by dehydration of the corresponding 1-methyl-6-phenacyl-pteridine-2,4,7(1H,3H,8H)-triones is reported in the article. It was shown that their alkylation by butyl chloroacetate in basic medium proceeded by the N3-atom of...

Cite
Kazunin MS, Voskoboynik OY, Shishkina SV, et al. A Simple and Convenient Method for the Synthesis of 1-Methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones and Their Substituted Derivatives. Acta Chim Slov. 2020;67(2):586-593
Kazunin, M. S., Voskoboynik, O. Y., Shishkina, S. V., Antypenko, O. M., & Kovalenko, S. I. (2020). A Simple and Convenient Method for the Synthesis of 1-Methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones and Their Substituted Derivatives. Acta chimica Slovenica, 67(2), 586-593.
Kazunin, Maxim Stanislavovich, et al. "A Simple and Convenient Method for the Synthesis of 1-Methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones and Their Substituted Derivatives." Acta chimica Slovenica vol. 67,2 (2020): 586-593.
Kazunin MS, Voskoboynik OY, Shishkina SV, Antypenko OM, Kovalenko SI. A Simple and Convenient Method for the Synthesis of 1-Methyl-7-arylfuro[3,2-g]pteridine-2,4(1H,3H)-diones and Their Substituted Derivatives. Acta Chim Slov. 2020 Jun;67(2):586-593. PMID: 33855556.
Copy Download .nbib Format: NLM
An Integrated High Throughput Experimentation/Predictive QSAR Modeling Approach to .

Polymers

Ehm C, Vittoria A, Goryunov GP, Izmer VV, Kononovich DS, Samsonov OV, Di Girolamo R, Budzelaar PHM, Voskoboynikov AZ, Busico V, Uborsky DV, Cipullo R.
PMID: 32349220
Polymers (Basel). 2020 Apr 27;12(5). doi: 10.3390/polym12051005.

Compared to heterogenous Ziegler-Natta systems (ZNS),

Cite
Ehm C, Vittoria A, Goryunov GP, et al. An Integrated High Throughput Experimentation/Predictive QSAR Modeling Approach to . Polymers (Basel). 2020;12(5)doi: 10.3390/polym12051005.
Ehm, C., Vittoria, A., Goryunov, G. P., Izmer, V. V., Kononovich, D. S., Samsonov, O. V., Di Girolamo, R., Budzelaar, P. H. M., Voskoboynikov, A. Z., Busico, V., Uborsky, D. V., & Cipullo, R. (2020). An Integrated High Throughput Experimentation/Predictive QSAR Modeling Approach to . Polymers, 12(5), . https://doi.org/10.3390/polym12051005
Ehm, Christian, et al. "An Integrated High Throughput Experimentation/Predictive QSAR Modeling Approach to ." Polymers vol. 12,5 (2020). doi: https://doi.org/10.3390/polym12051005
Ehm C, Vittoria A, Goryunov GP, Izmer VV, Kononovich DS, Samsonov OV, Di Girolamo R, Budzelaar PHM, Voskoboynikov AZ, Busico V, Uborsky DV, Cipullo R. An Integrated High Throughput Experimentation/Predictive QSAR Modeling Approach to . Polymers (Basel). 2020 Apr 27;12(5). doi: 10.3390/polym12051005. PMID: 32349220; PMCID: PMC7284373.
Copy Download .nbib Format: NLM
Quinazoline-containing Hydrazydes of Dicarboxylic Acids and Products of Their Structural Modification: A Novel Class of Anti-inflammatory Agents.

Acta chimica Slovenica

Krasovska N, Stavytskyi V, Nosulenko I, Karpenko O, Voskoboinik O, Kovalenko S.
PMID: 34738126
Acta Chim Slov. 2021 Jun;68(2):395-403.

The synthesis of hydrazides formed by quinazolin-4(3H)-ylidenehydrazine and dicarboxylic acids, as well as their further modification are described in the present manuscript. It was shown that above-mentioned hydrazides may be obtained via acylation of initial quinazolin-4(3H)-ylidenehydrazine by corresponding acylhalides,...

Cite
Krasovska N, Stavytskyi V, Nosulenko I, et al. Quinazoline-containing Hydrazydes of Dicarboxylic Acids and Products of Their Structural Modification: A Novel Class of Anti-inflammatory Agents. Acta Chim Slov. 2021;68(2):395-403
Krasovska, N., Stavytskyi, V., Nosulenko, I., Karpenko, O., Voskoboinik, O., & Kovalenko, S. (2021). Quinazoline-containing Hydrazydes of Dicarboxylic Acids and Products of Their Structural Modification: A Novel Class of Anti-inflammatory Agents. Acta chimica Slovenica, 68(2), 395-403.
Krasovska, Nataliia, et al. "Quinazoline-containing Hydrazydes of Dicarboxylic Acids and Products of Their Structural Modification: A Novel Class of Anti-inflammatory Agents." Acta chimica Slovenica vol. 68,2 (2021): 395-403.
Krasovska N, Stavytskyi V, Nosulenko I, Karpenko O, Voskoboinik O, Kovalenko S. Quinazoline-containing Hydrazydes of Dicarboxylic Acids and Products of Their Structural Modification: A Novel Class of Anti-inflammatory Agents. Acta Chim Slov. 2021 Jun;68(2):395-403. PMID: 34738126.
Copy Download .nbib Format: NLM
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ.
PMID: 34800678
Ann Oncol. 2021 Nov 18; doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18.

BACKGROUND: In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab as monotherapy or in combination with pembrolizumab.PATIENTS AND METHODS: Part A enrolled patients...

Cite
Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol. 2021;doi: 10.1016/j.annonc.2021.11.002.
Niu, J., Maurice-Dror, C., Lee, D. H., Kim, D. W., Nagrial, A., Voskoboynik, M., Chung, H. C., Mileham, K., Vaishampayan, U., Rasco, D., Golan, T., Bauer, T. M., Jimeno, A., Chung, V., Chartash, E., Lala, M., Chen, Q., Healy, J. A., & Ahn, M. J. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, . https://doi.org/10.1016/j.annonc.2021.11.002
Niu, J, et al. "First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer." Annals of oncology : official journal of the European Society for Medical Oncology vol. (2021). doi: https://doi.org/10.1016/j.annonc.2021.11.002
Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol. 2021 Nov 18; doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18. PMID: 34800678.
Copy Download .nbib Format: NLM
Combination therapies for the treatment of advanced melanoma: a review of current evidence.

Biochemistry research international

Voskoboynik M, Arkenau HT.
PMID: 24693430
Biochem Res Int. 2014;2014:307059. doi: 10.1155/2014/307059. Epub 2014 Feb 12.

The treatment of advanced melanoma has been revolutionised in recent years with the advent of a range of new therapies. BRAF inhibitors, such as vemurafenib, have demonstrated improvements in the overall survival of patients with advanced melanoma that harbour...

Cite
Voskoboynik M, Arkenau HT. Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int. 2014;2014:307059doi: 10.1155/2014/307059.
Voskoboynik, M., & Arkenau, H. T. (2014). Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochemistry research international, 2014307059. https://doi.org/10.1155/2014/307059
Voskoboynik, Mark, and Arkenau, Hendrik-Tobias. "Combination therapies for the treatment of advanced melanoma: a review of current evidence." Biochemistry research international vol. 2014 (2014): 307059. doi: https://doi.org/10.1155/2014/307059
Voskoboynik M, Arkenau HT. Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int. 2014;2014:307059. doi: 10.1155/2014/307059. Epub 2014 Feb 12. PMID: 24693430; PMCID: PMC3944792.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries